Tatarstan Cancer Center, Kazan
Kamalov I.A. ― Cand. Med. Sc., oncologist, doctor of ultrasonic diagnostics of the Tatarstan Cancer Center
29 Sibirskiy Trakt, Kazan, Russian Federation, 420029, tel.: (843) 519-27-03, +7-917-267-55-11, e-mail: email@example.com
Introduction. Improvement of ultrasonic methods of research has opened up new possibilities for studying two-way communication between the procoagulant activity of malignant tumors and the growth of the metastatic potential of tumor cells. The aim of this study is to identify the relationship of ultrasonographic signs of idiopathic venous thrombosis and malignancies.
Methods. Surveyed and observed 215 patients with malignant tumors. Patients were divided into two homogeneous groups: main group ― 105 patients; a control group of 110 patients. A sign of the difference between the groups was the presence of idiopathic venous thromboembolism in patients of the main group.
Results. Within two years after the special treatment, distant metastases of malignant tumors were found in 33% of patients the main group and in 8% of patients in the control group. Diagnosis of distant metastases of malignant tumors coincided with echographic signs of blood clots in the previously intact segment of the vein and the progression of venous thrombosis: in the main group ― 60% of patients; in the control group ― 56% of patients.
Conclusion. Dynamic changes of ultrasonographic signs of idiopathic venous thrombosis are closely linked with the progression of cancer and can be used as a prognostic marker of metastasis of malignant tumors.
Key words: idiopathic venous thrombosis, procoagulant activity malignancies, metastasis of malignant tumors.
1. Marushchak E.A., A.R. Zubarev The role of ultrasound diagnosis in determining the surgical approach in patients with deep vein thrombosis of a floating system vena cava inferior. Meditsinskaya vizualizatsiya, 2013, no. 3, p. 121 (in Russ.).
2. Orel M.G. The incidence of thrombosis of the deep veins of the lower extremities in thrombotic lesions of the saphenous veins. Novosti khirurgii, 2015, no.1, pp. 63-69 (in Russ.).
3. Petri A., Sebin K. Naglyadnaya statistika v meditsine [Transparent statistics in medicine]. Moscow: Geotar-Med, 2003. 144 p.
4. Shilova A.N., Barkagan Z.S. Current data on the incidence and pathogenesis onkotrombozov. Tromboz. Gemostaz. Reologiya, 2006, no. 1, pp. 6-15 (in Russ.).
5. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit. Rev. Oncol Hematol, 2004, vol. 50, rr. 187-196.
6. Falanga A., Marchetti M., Vignoli A., Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin. Adv. Hematol. Oncol, 2003, vol. 1, rr. 673-678.
7. Hoffman E.A., Gizelska K., Mirowski M., Mielicki W. Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro. Contemp. Oncol (Pozn), 2015, vol. 19 (2), rr. 108-112.
8. Lee A.Y., Levine M.N. Venous Thromboembolism and Cancer: Risks and Outcomes. Circulation, 2003, vol. 107 (23), rr. 17-21.
9. Lee A.Y. Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms. Hematology Am. Soc. Hematol. Educ. Program, 2006, rr. 438-443.
10. Lima L.G., Monteiro R.Q. Activation of blood coagulation in cancer: implications for tumour progression. Bioscience Reports, 2013, vol. 33 (5).
11. Sampson M.T., Kakkar A.K. Coagulation proteases and human cancer. Biochem. Soc. Trans, 2002, vol. 30, rr. 201-207.